Fig. 3
From: Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
Modified CSC-workflow allows for the interrogation of the AML surfaceome in primary patient samples. A 621 surface proteins identified with our modified CSC technology 7 clinical samples and 1 AML cell line (OCI-AML3), separated into CD proteins (black, 163) and non-CD proteins (red, 458). B Expression levels of CD proteins identified by CSC. Heatmap intensity indicates the log10 average of iBAQ. C Overview of filtering strategy to eliminate targets with abundant expression on normal healthy tissue using publicly available gene expression databases. Furthermore, only proteins that were detected in at least half of the primary patient samples were considered. As a result, 76 proteins remain as potential candidates for manual evaluation. D Protein expression of 5 new putative targets (top, in green) and 6 markers currently being investigated (bottom, in grey) as immunotherapeutic targets in AML samples